



BÖLÜM 6

TRANSVERS MİYELİT

Dilek İŞCAN¹
Ümit SATILMIŞ²

GİRİŞ

Transvers miyelit (TM) enflamasyonun neden olduğu omuriliğin nadir görülen, yıkıcı nörolojik semptomları olan bir tablosudur (1). TM paraenfeksiyöz, para-neoplastik, ilaç/toksin kaynaklı, sistemik otoimmün bozukluklar ve edinilmiş demiyelinizan hastalıklar sonucu gelişebilir. Seviye veren duyu kusuru, parezi, idrar-gaita retansiyonu ve impotans gibi otonomik tutuluş bulguları ile prezente olabilir (2). Semptomlar tipik olarak saatler, günler içinde yerleşir, günler veya haftalar içinde kötüleşir (1). Nörogörüntüleme ve Beyin omurilik sıvısı (BOS) alıřmaları merkezi sinir sistemi içinde inflamasyonu gösteriyorsa otoimmün, inflamatuvar ve enfeksiyöz etiyolojiler araştırılmalıdır. Günümüzde ortaya çıkan yeni enfeksiyonlar, nüfusun kalabalık olmasından ve ulaşımın kolaylığından kaynaklanan hızlı yayılım ve yeni geliştirilen aşular, immun yanıt sonucu gelişen TM'nin önemini arttırmıştır. Erken teşhis ve etkili immünoterapi gelecekteki engellilięi en aza indirmek ve hatta önlemek için kritik öneme sahiptir.

TRANSVERS MİYELİT

Miyelit ve miyelopati terimleri sıklıkla birbirinin yerine kullanılır, her ikisi de omurilięi etkileyen bir lezyonu düşündürse de farklı anlamlara sahiptir. Miyelopati, belirli bir etiyolojiye işaret etmeyen geniş, genel bir terim iken miyelit,

¹Dr. Öğr. Üyesi, Nięde Ömer Halisdemir Üniversitesi, Tıp Fakültesi, Nöroloji AD, dilekiscann@gmail.com

²Uzm. Dr., Elbistan Devlet Hastanesi, Nöroloji Klinięi mitstlms@gmail.com

KAYNAKLAR

1. West, T.W., *Transverse myelitis--a review of the presentation, diagnosis, and initial management*. Discov Med, 2013. **16**(88): p. 167-77.
2. Beh, S.C., et al., *Transverse myelitis*. Neurol Clin, 2013. **31**(1): p. 79-138.
3. Oppenheim, H., *Zum capitel der myelitis*. Berl Klin Wchnschr, 1891. **28**: p. 761.
4. *Proposed diagnostic criteria and nosology of acute transverse myelitis*. Neurology, 2002. **59**(4): p. 499-505.
5. Berman, M., et al., *Acute transverse myelitis: incidence and etiologic considerations*. Neurology, 1981. **31**(8): p. 966-71.
6. Jeffery, D.R., R.N. Mandler, and L.E. Davis, *Transverse myelitis. Retrospective analysis of 33 cases, with differentiation of cases associated with multiple sclerosis and parainfectious events*. Arch Neurol, 1993. **50**(5): p. 532-5.
7. Christensen, P.B., et al., *Clinical course and long-term prognosis of acute transverse myelopathy*. Acta Neurol Scand, 1990. **81**(5): p. 431-5.
8. Young, J., et al., *Clinically isolated acute transverse myelitis: prognostic features and incidence*. Mult Scler, 2009. **15**(11): p. 1295-302.
9. Klein, N.P., et al., *Rates of autoimmune diseases in Kaiser Permanente for use in vaccine adverse event safety studies*. Vaccine, 2010. **28**(4): p. 1062-8.
10. Altrocchi, P.H., *ACUTE TRANSVERSE MYELOPATHY*. Arch Neurol, 1963. **9**: p. 111-9.
11. Bhat, A., et al., *The epidemiology of transverse myelitis*. Autoimmun Rev, 2010. **9**(5): p. A395-9.
12. Katz, J. and A. Ropper, *Progressive necrotic myelopathy: Clinical course in 9 patients*. Archives of neurology, 2000. **57**: p. 355-61.
13. Mirich, D.R., et al., *Subacute necrotizing myelopathy: MR imaging in four pathologically proved cases*. AJNR Am J Neuroradiol, 1991. **12**(6): p. 1077-83.
14. Kontogiorgi, M., et al., *Mycoplasma Pneumoniae Associated Transverse Myelitis in a 26-Year-Old Male*. 2013. 2013.
15. Kaplin, A.I., et al., *Diagnosis and management of acute myelopathies*. Neurologist, 2005. **11**(1): p. 2-18.
16. Piper, P.G., *Disseminated lupus erythematosus with involvement of the spinal cord*. J Am Med Assoc, 1953. **153**(3): p. 215-7.
17. Andrianakos, A.A., et al., *Transverse myelopathy in systemic lupus erythematosus. Report of three cases and review of the literature*. Ann Intern Med, 1975. **83**(5): p. 616-24.
18. Garcia-Zozaya, I.A., *Acute transverse myelitis in a 7-month-old boy*. J Spinal Cord Med, 2001. **24**(2): p. 114-8.
19. de Macedo, D.D., J.P. de Mattos, and T.M. Borges, *[Transverse myelopathy and systemic lupus erythematosus. Report of a case and review of the literature]*. Arq Neuropsiquiatr, 1979. **37**(1): p. 76-84.
20. Trecker, C.C., Kozubal, D. E., Kaplin, A. I., & Kerr, D. A., *Transverse Myelitis:Patho-*

- genesis, Diagnosis and Management*. Blue Books of Neurology. 2010.
21. Içöz, S., et al., *Enhanced IL-6 production in aquaporin-4 antibody positive neuromyelitis optica patients*. Int J Neurosci, 2010. **120**(1): p. 71-5.
 22. West, T.W., C. Hess, and B.A. Cree, *Acute transverse myelitis: demyelinating, inflammatory, and infectious myelopathies*. Semin Neurol, 2012. **32**(2): p. 97-113.
 23. Sá, M.J., *Acute transverse myelitis: a practical reappraisal*. Autoimmun Rev, 2009. **9**(2): p. 128-31.
 24. Pidcock, F.S., et al., *Acute transverse myelitis in childhood: center-based analysis of 47 cases*. Neurology, 2007. **68**(18): p. 1474-80.
 25. Awad, A. and O. Stüve, *Idiopathic transverse myelitis and neuromyelitis optica: clinical profiles, pathophysiology and therapeutic choices*. Curr Neuropharmacol, 2011. **9**(3): p. 417-28.
 26. Schmalstieg, W.F. and B.G. Weinshenker, *Approach to acute or subacute myelopathy*. Neurology, 2010. **75**(18 Suppl 1): p. S2-8.
 27. Harzheim, M., et al., *Discriminatory features of acute transverse myelitis: a retrospective analysis of 45 patients*. J Neurol Sci, 2004. **217**(2): p. 217-23.
 28. de Seze, J., et al., *Idiopathic acute transverse myelitis: application of the recent diagnostic criteria*. Neurology, 2005. **65**(12): p. 1950-3.
 29. Tartaglino, L.M., et al., *Multiple sclerosis in the spinal cord: MR appearance and correlation with clinical parameters*. Radiology, 1995. **195**(3): p. 725-32.
 30. Bergamaschi, R., et al., *Oligoclonal bands in Devic's neuromyelitis optica and multiple sclerosis: differences in repeated cerebrospinal fluid examinations*. Mult Scler, 2004. **10**(1): p. 2-4.
 31. Wingerchuk, D.M., et al., *The spectrum of neuromyelitis optica*. Lancet Neurol, 2007. **6**(9): p. 805-15.
 32. Lennon, V.A., et al., *A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis*. Lancet, 2004. **364**(9451): p. 2106-12.
 33. Wingerchuk, D.M., et al., *Revised diagnostic criteria for neuromyelitis optica*. Neurology, 2006. **66**(10): p. 1485-9.
 34. Collongues, N., et al., *Neuromyelitis optica in France: a multicenter study of 125 patients*. Neurology, 2010. **74**(9): p. 736-42.
 35. Pittock, S.J., et al., *Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression*. Arch Neurol, 2006. **63**(7): p. 964-8.
 36. Matà, S. and F. Lolli, *Neuromyelitis optica: an update*. J Neurol Sci, 2011. **303**(1-2): p. 13-21.
 37. Garg, R.K. and V.K. Paliwal, *Spectrum of neurological complications following COVID-19 vaccination*. Neurol Sci, 2022. **43**(1): p. 3-40.
 38. Finsterer, J., *Neurological side effects of SARS-CoV-2 vaccinations*. Acta Neurol Scand, 2022. **145**(1): p. 5-9.
 39. Román, G.C., et al., *Acute Transverse Myelitis (ATM): Clinical Review of 43 Patients With COVID-19-Associated ATM and 3 Post-Vaccination ATM Serious Adverse*

- Events With the ChAdOx1 nCoV-19 Vaccine (AZD1222)*. *Front Immunol*, 2021. **12**: p. 653786.
40. Masson, C., [*Acute transverse myelopathy: inflammatory or ischemic?*]. *Presse Med*, 2005. **34**(12): p. 869-77.
41. Scott, T.F., et al., *Evidence-based guideline: clinical evaluation and treatment of transverse myelitis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology*. *Neurology*, 2011. **77**(24): p. 2128-34.
42. Sébire, G., et al., *High dose methylprednisolone in severe acute transverse myelopathy*. *Arch Dis Child*, 1997. **76**(2): p. 167-8.
43. Llifriu, S., et al., *Plasma exchange for acute attacks of CNS demyelination: Predictors of improvement at 6 months*. *Neurology*, 2009. **73**(12): p. 949-53.
44. Keegan, M., et al., *Plasma exchange for severe attacks of CNS demyelination: predictors of response*. *Neurology*, 2002. **58**(1): p. 143-6.